Pherecydes Pharma S.A. (ALPHE.PA)
Pherecydes Pharma S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Romainville, FR. The stock last traded at $2.00, down 0.50% on the session, giving a market capitalisation of $15.8M. Its beta of 0.99 implies it has historically moved less than the broad market.
Pherecydes Pharma S.A. focuses on developing antimicrobial treatments by leveraging bacteriophage viruses, also known as phages. The company's pipeline includes a range of therapeutic options: phages engineered to combat Staphylococcus aureus in bone/joint and diabetic foot ulcer infections; phages targeting Pseudomonas aeruginosa for complicated urinary tract infections; and phages designed to address Escherichia coli in respiratory tract infections. The firm was founded in 2006 and is headquartered in Romainville, France.
Pherecydes Pharma S.A. is most often compared with the following Healthcare names: